{"brief_title": "TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)", "brief_summary": "The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.", "condition": "Non-small Cell Lung Cancer", "intervention_type": "Drug", "intervention_name": "TLK286, cisplatin", "description": "TLK286 administered once every 3 weeks (\u00b1 2 days) at two dose-ranging levels (750 mg/m\u00b2) and 1,000 mg/\u00b2) in combination with two dose levels of cisplatin (75 mg/m\u00b2 and 100 mg/m\u00b2) of cisplatin once every 3 weeks (\u00b1 2 days).", "criteria": "Inclusion Criteria: - 18 years of age or older - Histologically confirmed non-small cell lung cancer - Stage IV or IIIB - Measurable disease by RECIST - ECOG performance status of 0-1 - Adequate liver and renal function - Adequate bone marrow reserve Exclusion Criteria: - History of bone marrow transplantation or stem cell support - Pregnant or lactating women", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00077883.xml"}